Inclusion criteria:
Age 18 to 70 years.
Confirmation of HSCT candidacy by the transplant team.
Adequate performance status, i.e. Eastern Cooperative Oncology Group (ECOG) score from 0 to 2.
Ability to swallow and take capsules orally at the time of intervention and the possibility of taking them for at least one week after conditioning.
Patients’ agreement to standard mucositis prevention care according to the center’s protocol (prevention: chlorhexidine and normal saline mouthwash, treatment: diphenhydramine + AlMg + nystatin + lidocaine cocktail and, if needed and available, gelclair mouthwash and mucosamine spray).
Written informed consent.
Exclusion criteria:
Known hypersensitivity to Curcumin, Turmeric, or components of the nanomicelle product.
Chronic systemic corticosteroid use at a dose equivalent to >10 mg prednisone daily for 14 days prior to conditioning.
Regular use of supplements or herbs with anti-inflammatory-antioxidant effects or containing Piperine for 7 days prior to conditioning, including high doses of vitamins A-C-E, selenium, non-study turmeric products, ginger, chamomile.
Stable oral anticoagulant therapy or dual antiplatelet therapy that cannot be adjusted. Single low-dose aspirin use is acceptable and will be recorded.
AST or ALT > 3 times the upper limit of normal, or total bilirubin > 2 times the upper limit of normal, or eGFR < 30 mL/min/1.73 m².
Concurrent participation in another interventional trial that directly affects mucositis, sleep, appetite, or supportive care.
Pregnancy or lactation.